PCL
MCID: PLS016
MIFTS: 42

Plasma Cell Leukemia (PCL) malady

Categories: Rare diseases, Cancer diseases, Blood diseases

Aliases & Classifications for Plasma Cell Leukemia

Aliases & Descriptions for Plasma Cell Leukemia:

Name: Plasma Cell Leukemia 50 56 52
Leukemia, Plasma Cell 50 69
Pcl 56

Characteristics:

Orphanet epidemiological data:

56
plasma cell leukemia
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adult,Elderly; Age of death: adult,elderly;

Classifications:



External Ids:

Orphanet 56 ORPHA454714
ICD10 via Orphanet 34 C90.1
ICD10 33 C90.1

Summaries for Plasma Cell Leukemia

NIH Rare Diseases : 50 plasma cell leukemia (pcl) is a rare and aggressive form of multiple myeloma that involves high levels of plasma cells circulating in the peripheral blood. the signs and symptoms of pcl include aggressive clinical features, such as extramedullary disease, bone marrow failure, advanced stage disease and expression of distinct immunophenotypic markers. different types of treatments are available for patients with pcl. some treatments are standard (the currently used treatment), and some are being tested in clinical trials. for detailed information on the available treatment options, please visit the following link. http://www.cancer.gov/cancertopics/pdq/treatment/myeloma/patient/page4 last updated: 2/20/2014

MalaCards based summary : Plasma Cell Leukemia, also known as leukemia, plasma cell, is related to multiple myeloma and plasmacytic leukemia. An important gene associated with Plasma Cell Leukemia is NCAM1 (Neural Cell Adhesion Molecule 1), and among its related pathways/superpathways are Cytokine Signaling in Immune system and MAPK Signaling: Mitogen Stimulation Pathway. The drugs Methotrexate and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and testes, and related phenotype is vision/eye.

Wikipedia : 71 Plasma cell leukemia (PCL), a lymphoproliferative disorder, is a rare cancer involving a subtype of... more...

Related Diseases for Plasma Cell Leukemia

Diseases related to Plasma Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 62)
id Related Disease Score Top Affiliating Genes
1 multiple myeloma 11.3
2 plasmacytic leukemia 11.0
3 lymphedema, hereditary, ia 10.8
4 leukemia 10.8
5 microcystic adenoma 10.1 CCND1 IRF4
6 13q12.3 microdeletion syndrome 10.1 CCND1 FGFR3
7 mesothelioma, somatic 10.0 CCND1 IRF4
8 papillary transitional carcinoma 10.0 CCND1 FGFR3
9 gingival recession 10.0 CCND1 IRF4
10 ectodermal dysplasia 10.0 CCND1 IRF4
11 peripheral nervous system ganglioneuroblastoma 9.9 MAF NCAM1
12 childhood pleomorphic rhabdomyosarcoma 9.9 MAF NCAM1
13 placenta praevia 9.9 CCND1 FGFR3
14 lymphoma 9.9
15 theileriasis 9.9 CCND1 NCAM1
16 nodular tenosynovitis 9.9 MAF NCAM1
17 pituitary carcinoma 9.9 CCND1 NCAM1
18 autonomic nervous system neoplasm 9.9 CCND1 FGFR3
19 ethmoid sinus schneiderian papilloma 9.9 FGFR3 NCAM1
20 bladder disease 9.9 CCND1 IRF4
21 plasmacytoma 9.9
22 personality disorder 9.8
23 angioimmunoblastic t-cell lymphoma 9.7
24 colorectal cancer 9.7
25 lung cancer 9.7
26 gastric cancer 9.7
27 human herpesvirus 8 9.7
28 macroglobulinemia 9.7
29 amyloidosis 9.7
30 meningitis 9.7
31 hematopoietic stem cell transplantation 9.7
32 myelofibrosis 9.7
33 peripheral t-cell lymphoma 9.7
34 paraplegia 9.5
35 disseminated intravascular coagulation 9.5
36 t-cell leukemia 9.5
37 thyroiditis 9.5
38 hepatitis c virus 9.5
39 hepatitis c 9.5
40 measles 9.5
41 cholecystitis 9.5
42 myeloid leukemia 9.5
43 acalculous cholecystitis 9.5
44 pulmonary hypertension 9.5
45 hairy cell leukemia 9.5
46 adult t-cell leukemia 9.5
47 cystadenocarcinoma 9.5
48 chronic lymphocytic leukemia 9.5
49 serous cystadenocarcinoma 9.5
50 crohn's disease 9.5

Graphical network of the top 20 diseases related to Plasma Cell Leukemia:



Diseases related to Plasma Cell Leukemia

Symptoms & Phenotypes for Plasma Cell Leukemia

MGI Mouse Phenotypes related to Plasma Cell Leukemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 8.92 NCAM1 CCND1 FGFR3 MAF

Drugs & Therapeutics for Plasma Cell Leukemia

Drugs for Plasma Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 498)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
3
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
4
Vidarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 24356-66-9 32326 21704
5
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
6
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
8
Lenograstim Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 135968-09-1
9
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
10
Thiotepa Approved Phase 4,Phase 2,Phase 1 52-24-4 5453
11
Menthol Approved Phase 4,Phase 1 2216-51-5 16666
12
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 54575, 6560146 143
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
14
Vitamin C Approved, Nutraceutical Phase 4,Phase 1 50-81-7 5785 54670067
15 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
16 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
18 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Trace Elements Phase 4,Phase 3,Phase 1,Phase 2
24 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
25
Treosulfan Phase 4,Phase 2 299-75-2 9296
26 Hormones Phase 4,Phase 3,Phase 2,Phase 1
27 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
29 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Prednisolone hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1
32 6-Mercaptopurine Phase 4,Phase 3,Phase 2,Phase 1
33 Prednisolone phosphate Phase 4,Phase 3,Phase 2,Phase 1
34 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
38 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Antilymphocyte Serum Phase 4,Phase 2,Phase 1
40 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
41 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
42 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
43 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1
44 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Micronutrients Phase 4,Phase 3,Phase 1,Phase 2
46 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
50 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 772)
id Name Status NCT ID Phase
1 Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America Completed NCT02559583 Phase 4
2 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
3 Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor Completed NCT01362985 Phase 4
4 Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4
5 ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
6 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4
7 Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid Recruiting NCT01906671 Phase 4
8 Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and Controls Not yet recruiting NCT02809222 Phase 4
9 Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma Unknown status NCT00002599 Phase 3
10 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3
11 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
12 Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia Unknown status NCT01670812 Phase 3
13 MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis Unknown status NCT02270307 Phase 2, Phase 3
14 Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation Unknown status NCT01800643 Phase 2, Phase 3
15 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
16 Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer Completed NCT00002742 Phase 3
17 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3
18 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
19 Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma Completed NCT00002878 Phase 3
20 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00075478 Phase 3
21 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3
22 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3
23 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
24 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
25 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
26 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3
27 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
28 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
29 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
30 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
31 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00566332 Phase 3
32 SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma Completed NCT00002548 Phase 3
33 Epoetin Alfa in Treating Anemia in Patients With Solid Tumors Completed NCT00058331 Phase 3
34 Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer Completed NCT00516503 Phase 3
35 Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy Completed NCT00003600 Phase 3
36 Prevention of Left Ventricular Dysfunction During Chemotherapy Completed NCT01110824 Phase 3
37 A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. Completed NCT00300664 Phase 2, Phase 3
38 PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Completed NCT00048230 Phase 3
39 Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders. Completed NCT00145652 Phase 3
40 Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy Completed NCT01016548 Phase 3
41 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
42 Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients Completed NCT00103662 Phase 3
43 Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma Completed NCT00689936 Phase 3
44 A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039 Completed NCT00063726 Phase 3
45 Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma Completed NCT00179647 Phase 3
46 Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Completed NCT00086580 Phase 3
47 Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia Completed NCT00921375 Phase 3
48 GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia Completed NCT01518517 Phase 2, Phase 3
49 Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Recruiting NCT02991638 Phase 3
50 A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents Recruiting NCT02716233 Phase 3

Search NIH Clinical Center for Plasma Cell Leukemia

Genetic Tests for Plasma Cell Leukemia

Anatomical Context for Plasma Cell Leukemia

MalaCards organs/tissues related to Plasma Cell Leukemia:

39
Bone, Bone Marrow, Testes, T Cells, Skin, Thyroid, Spleen

Publications for Plasma Cell Leukemia

Articles related to Plasma Cell Leukemia:

(show top 50) (show all 368)
id Title Authors Year
1
Histone deacetylase inhibitors in plasma cell leukemia treatment: Effect of bone marrow microenvironment. ( 28043150 )
2017
2
Primary Plasma Cell Leukemia: Identity Card 2016. ( 26995215 )
2016
3
Plasma cell leukemia mimicking acute myeloid leukemia. ( 28092885 )
2016
4
Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du MyAclome. ( 27114594 )
2016
5
Plasma Cell Leukemia Presenting as a Chest Wall Mass: A Case Report. ( 27462235 )
2016
6
Multiple myeloma and secondary plasma cell leukemia. ( 27833979 )
2016
7
Radiographic features of plasma cell leukemia in the maxilla: A case report. ( 28035306 )
2016
8
Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma. ( 26505781 )
2016
9
Plasma Cell Leukemia With Prominent Hairy-cell Morphology. ( 27916226 )
2016
10
Hemorrhagic Skin Nodules and Plaques: A Diagnostic Clue to Underlying Primary Plasma Cell Leukemia. ( 27057024 )
2016
11
Plasma cell leukemia revealing a G6PD deficiency. ( 28034875 )
2016
12
Abrupt Development of Plasma Cell Leukemia in a Patient with Chronic Anemia under Follow-up. ( 26702753 )
2016
13
Primary plasma cell leukemia 2.0: advances in biology and clinical management. ( 27759436 )
2016
14
Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia. ( 28038447 )
2016
15
Plasma cell leukemia in North India: retrospective analysis of a distinct clinicohematological entity from a tertiary care center and review of literature. ( 27104188 )
2016
16
Novel Agents for the Treatment of Primary Plasma-Cell Leukemia: Lights and Shadows. ( 26506015 )
2016
17
MYEOV gene overexpression in primary plasma cell leukemia with t(11;14)(q13;q32). ( 27446453 )
2016
18
Rapid Fatal Acute Peripheral T-Cell Lymphoma Associated With IgG Plasma Cell Leukemia and IgA Hypergammaglobulinemia. ( 27824644 )
2016
19
Plasma cell leukemia: update on biology and therapy. ( 27819179 )
2016
20
Immunoglobulin D Multiple Myeloma, Plasma Cell Leukemia and Chronic Myelogenous Leukemia in a Single Patient Treated Simultaneously with Lenalidomide, Bortezomib, Dexamethasone and Imatinib. ( 27103978 )
2016
21
Progress in the Treatment of Primary Plasma Cell Leukemia. ( 27114588 )
2016
22
Confusing Hairy Cells in a Case of IgG Kappa Plasma Cell Leukemia. ( 27215099 )
2016
23
Primary plasma cell leukemia: A report of two cases of a rare and aggressive variant of plasma cell myeloma with the review of literature. ( 27721294 )
2016
24
Plasma cell leukemia mimicking hairy cell leukemia. ( 26013472 )
2015
25
Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. ( 26046463 )
2015
26
Atypical plasma cell leukemia mistaken for lymphocytosis on blood count. ( 26756052 )
2015
27
Characterization of a new human plasma cell leukemia cell line UHKT-944. ( 25600340 )
2015
28
Circulating reactive plasma cells in the setting of peripheral T-cell lymphoma mimicking plasma cell leukemia. ( 26539589 )
2015
29
Colonic plasmacytomas: a rare complication of plasma cell leukemia. ( 25926223 )
2015
30
Plasma cell leukemia: from biology to treatment. ( 25778450 )
2015
31
A case of CD10-negative angioimmunoblastic T cell lymphoma with leukemic change and increased plasma cells mimicking plasma cell leukemia: A case report. ( 26622708 )
2015
32
Simultaneous occurrence of angioimmunoblastic T-cell lymphoma and plasma cell leukemia. ( 25553298 )
2015
33
Synchronous Thyroid Involvement in Plasma Cell Leukemia Masquerading as Hashimoto's Thyroiditis: Role of Ancillary Cytology Techniques in Diagnostic Workup. ( 26330190 )
2015
34
Plasma cell leukemia: Clinicopathologic, immunophenotypic and cytogenetic characteristics of 4 cases. ( 25929729 )
2015
35
Lower gastrointestinal bleeding in a patient with Crohn's disease and plasma cell leukemia in remission. ( 26289474 )
2015
36
Pleomorphic plasma cell leukemia. ( 26904765 )
2015
37
Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine. ( 26263974 )
2015
38
Progression from light chain myeloma to secondary plasma cell leukemia accompanied by peripheral blood eosinophilia. ( 25951133 )
2015
39
Atypical blast morphology of primary plasma cell leukemia with renal involvement and plasmablasts in urine. ( 24828023 )
2014
40
Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. ( 24957143 )
2014
41
A case of CD138-/CD19+/CD4+ IgD plasma cell leukemia. ( 24659135 )
2014
42
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. ( 23958922 )
2014
43
A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation. ( 25337285 )
2014
44
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia. ( 24884320 )
2014
45
Resident rounds part III: plasma cell leukemia with initial cutaneous presentation. ( 25271340 )
2014
46
Melphalan/Total Body Irradiation-Conditioned Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients With Primary Plasma Cell Leukemia. ( 25172535 )
2014
47
Plasma cell leukemia: A case series from South India with emphasis on rarer variants. ( 25336792 )
2014
48
Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension. ( 24881743 )
2014
49
Two cases of nonsecretory multiple myeloma presenting as primary plasma cell leukemia. ( 25224200 )
2014
50
A case of CD138-/CD19+/CD4+ IgD plasma cell leukemia. ( 24715427 )
2014

Variations for Plasma Cell Leukemia

Expression for Plasma Cell Leukemia

Search GEO for disease gene expression data for Plasma Cell Leukemia.

Pathways for Plasma Cell Leukemia

GO Terms for Plasma Cell Leukemia

Biological processes related to Plasma Cell Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 interferon-gamma-mediated signaling pathway GO:0060333 8.62 IRF4 NCAM1

Molecular functions related to Plasma Cell Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 Ras guanyl-nucleotide exchange factor activity GO:0005088 8.62 FGFR3 NCAM1

Sources for Plasma Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....